• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Gain Therapeutics Inc.

    12/3/25 4:02:28 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GANX alert in real time by email
    S-8 1 tm2532477d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on December 3, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    Gain Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   85-1726310

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

         

    4800 Montgomery Lane

    Suite 220

    Bethesda, Maryland

     

     

     

    20814

    (Address of Principal Executive Offices)   (Zip Code)

     

    Gain Therapeutics, Inc. 2022 Equity Incentive Plan

    (Full title of the plan)

     

    Gene Mack

    Chief Executive Officer

    Gain Therapeutics, Inc.

    4800 Montgomery Lane

    Suite 220

    Bethesda, Maryland 20814

    (Name and address of agent for service)

     

    Tel: (301) 500-1556

    (Telephone number, including area code, of agent for service)

     

    Please send copies of all communications to:

    Steven M. Skolnick, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Tel: (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E to Form S-8, Gain Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (the “S-8 Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register 1,627,955 additional shares (“Evergreen Shares”) of the Registrant’s common stock, par value $0.0001 per share (“Common Stock”), reserved for issuance under the Gain Therapeutics, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), pursuant to the provisions of the 2022 Plan providing for an automatic annual increase by an amount equal to 6% of the total number of Common Stock shares outstanding on December 31 of the preceding calendar year. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this S-8 Registration Statement.

     

    This S-8 Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same benefit plan is effective. The Registrant previously registered Common Stock for issuance under the 2022 Plan under Registration Statements on Form S-8, filed with the Commission on July 15, 2022 (File No. 333-266142), May 30, 2023 (File No. 333-272255) and September 19, 2024 (File No. 333-282205). Pursuant to General Instruction E to Form S-8, this S-8 Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

     

     

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

      · The Registrant’s latest annual report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Commission on March 27, 2025;
      · The portions of the Registrant’s definitive proxy statement on Schedule 14A incorporated by reference to our Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on April 29, 2025;
      · The Registrant’s quarterly reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025, and September 30, 2025, filed on May 14, 2025, August 12, 2025 and November 12, 2025;
      · The Registrant’s Current Reports on Form 8-K filed with the Commission on January 7, 2025, January 15, 2025, April 10, 2025, June 24, 2025, June 30, 2025, July 17, 2025, October 6, 2025, October 9, 2025, and November 28, 2025;
      · The description of the securities contained in the Registrant’s Registration Statement on Form 8-A (Registration No. 001-40237) filed with the Commission on March 17, 2021, under Section 12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.1 to the Registrant’s annual report on Form 10-K for the year ended December 31, 2024 filed with the Commission on March 27, 2025.

     

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein; provided, however, that documents or information deemed to have been furnished and not filed in accordance with SEC rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

     

     

     

    Item 8. Exhibits.

     

     Exhibit No.   Exhibit Description  
    3.1   Amended and Restated Certificate of Incorporation of Gain Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 (File No. 001-40237) on Form 8-K filed with the Commission on March 22, 2021).
         
    3.2   Certificate of Amendment of Amended and Restated Certificate of Incorporation of Gain Therapeutics, Inc. filed with the Secretary of State of the State of Delaware on June 24, 2025 (incorporated by reference to Exhibit 3.1 (File No. 001-40237) on Form 8-K filed with the Commission on June 24, 2025).
         
    3.3   Amended and Restated Bylaws of Gain Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 on Form 8-K (File No. 001-40237) filed with the Commission on March 22, 2021).
         
    5.1*   Opinion of Lowenstein Sandler LLP.
         
    10.1   Gain Therapeutics, Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 4.6 to the Company’s Registration Statement on Form S-8 (File No. 333-266142), filed with the Commission on July 15, 2022).
         
    10.2   Form of 2022 Equity Incentive Plan Restricted Stock Unit Agreement (incorporated by reference to Exhibit 4.8 to the Company’s Registration Statement on Form S-8 (File No. 333-266142), filed with the Commission on July 15, 2022).
         
    10.3   Form of 2022 Equity Incentive Plan Stock Option Award Agreement (incorporated by reference to Exhibit 4.7 to the Company’s Registration Statement on Form S-8 (File No. 333-266142), filed with the Commission on July 15, 2022).
         
    23.1*   Consent of Ernst & Young AG.
         
    23.2*   Consent of Lowenstein Sandler LLP (included in Exhibit 5.1).
         
    24.1*   Power of Attorney (included on the signature page of this Registration Statement).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bethesda, State of Maryland, on December 3, 2025.

     

    GAIN THERAPEUTICS, INC.  
       
    By: /s/ Gene Mack  
      Gene Mack  
      Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gene Mack as attorney-in-fact with full power of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorneys and agents, or either of them, may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933, and any rules, regulations and requirements of the Securities and Exchange Commission thereunder, in connection with the registration of ordinary shares of the registrant under this registration statement, including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to this registration statement, to any and all amendments or supplements to this registration statement and to any and all instruments or documents filed as part of or in connection with this registration statement or any and all amendments thereto; and each of the undersigned hereby ratifies and confirms all that such attorneys and agents, or either of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

    Signature   Title   Date
             
    /s/ Gene Mack   Chief Executive Officer and Director   December 3, 2025
    Gene Mack   (Principal Executive Officer)    
             

    /s/ Gianluca Fuggetta

      Senior Vice President Finance  

    December 3, 2025

    Gianluca Fuggetta   (Principal Financial Officer and Principal Accounting Officer)    
             

    /s/ Khalid Islam

    Khalid Islam

      Chairman of the Board of Directors  

    December 3, 2025

           
             

    /s/ Dov Goldstein

    Dov Goldstein

      Director  

    December 3, 2025

       
             

    /s/ Hans Peter Hasler

    Hans Peter Hasler

      Director  

    December 3, 2025

       
             

    /s/ Gwen Melincoff

    Gwen Melincoff

      Director  

    December 3, 2025

       
             

    /s/ Claude Nicaise

    Claude Nicaise

      Director  

    December 3, 2025

       
             
    /s/ Jeffrey Riley   Director  

    December 3, 2025

    Jeffrey Riley        

     

     

     

    Get the next $GANX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GANX

    DatePrice TargetRatingAnalyst
    3/7/2025$12.00Sector Outperform
    Scotiabank
    12/6/2024$7.00Buy
    ROTH MKM
    8/14/2024$8.00Outperform
    Oppenheimer
    11/3/2021$21.00Buy
    B. Riley Securities
    More analyst ratings

    $GANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Interim CEO Mack Gene bought $14,544 worth of shares (14,400 units at $1.01) (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    8/12/24 5:23:31 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Islam Khalid bought $49,940 worth of shares (50,000 units at $1.00) (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    8/12/24 5:23:30 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Richman Eric I bought $20,670 worth of shares (17,000 units at $1.22), increasing direct ownership by 6% to 289,629 units (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    7/1/24 5:00:27 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Islam Khalid

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:23 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Richman Eric I

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:19 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Nicaise Claude

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:22 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    SEC Filings

    View All

    SEC Form S-8 filed by Gain Therapeutics Inc.

    S-8 - Gain Therapeutics, Inc. (0001819411) (Filer)

    12/3/25 4:02:28 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

    11/28/25 4:03:07 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Gain Therapeutics Inc.

    424B5 - Gain Therapeutics, Inc. (0001819411) (Filer)

    11/28/25 4:01:34 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Leadership Updates

    Live Leadership Updates

    View All

    Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

    Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, who has served as the Company's Chief Financial Officer since April 2024 and interim Chief Executive Officer since June 2024, has been appointed President and Chief Executive Officer, effective January 6, 2025. Mr. Mack has also been appointed as a me

    1/7/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

    Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the Company appointed Gene Mack, the Company's current Chief Financial Officer, as interim Chief Executive Officer, effective June 25, 2024. Mr. Mack will retain his role as Chief Finan

    6/27/24 4:08:08 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

    BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record of successful financing, M&A and other strategic transactions combined with his scientific background and career as an equity research analyst ideally complement our executive man

    4/8/24 9:25:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Financials

    Live finance-specific insights

    View All

    Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

    BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. "The first quarter of 2025 marked yet another exciting milestone for Gain with the first administration of GT-02287, our lead drug candidate in development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation, to participants with Parkinson's disease in our ongoing Phase 1b study which began enrollment in early M

    5/14/25 7:30:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

    BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO

    3/27/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

    BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. "The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson's disease in patients with or without the GBA1 mutation. Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson's Disease and Movement

    11/14/24 4:05:00 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gain Therapeutics Inc.

    SC 13G/A - Gain Therapeutics, Inc. (0001819411) (Subject)

    3/29/21 11:59:04 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

    GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced mouse PD model GT-02287 improves mitochondrial function by facilitating GCase trafficking to the mitochondria in patient-derived fibroblasts harboring GBA1 mutation BETHESDA, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation was made at the Society

    11/20/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

    Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of 21 participants in Phase 1b study evaluating GT-02287 in Parkinson's Disease with or without GBA1 mutations during 3Q 2025 Received approval from the Australian health authorities to extend the duration of the Phase 1b study, allowing participants to continue treatment with GT-02287 for a total of 12 months; with a majority of subjects electing to participate in the study extension Analysis of functional changes and biomarker activity at 90 days expected to be available during 4Q

    11/12/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics to Present at Neuroscience 2025

    BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the Society for Neuroscience annual meeting, Neuroscience 2025, being held November 15th–19th in San Diego, CA. Details are as follows: Session Type: PosterSession Number: PSTR438Session Title: Developing Parkinson's Disease Therapeutic Strategies Using Cellular Models Poster Title: "GT-02287, a small molecule allosteric modulator of lysosomal enzyme glucocerebrosidase (GCase), acts at both lysos

    10/30/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Gain Therapeutics with a new price target

    Scotiabank initiated coverage of Gain Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

    3/7/25 8:20:06 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Gain Therapeutics with a new price target

    ROTH MKM initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $7.00

    12/6/24 7:48:38 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Gain Therapeutics with a new price target

    Oppenheimer resumed coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $8.00

    8/14/24 7:36:01 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care